3 months The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings Benzinga      

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.

Synthetic Biologics, Inc. (NYSE: SYN) was among the biggest advancers, as the stock reacted to its quarterly results. On the other hand, Nektar Therapeutics (NASDAQ: NKTR) came under pressure following negative results from a late-study of its investigational cancer drug in combination of Bristol-Myers Squibb Company’s (NYSE: BMY) Opdivo.

Bristol-Myers Squib, meanwhile, received the Food and Drug Administration’s approval for its Lag-3 antibody relatilimab, in combination with Opdivo, for the treatment of advanced melanoma.

Here are the key catalysts that could move the needle on biopharma stocks in the unfolding week:

Conferences

AD/PD 2022: International Conference On Alzheimer’s And Parkinson’s Diseases And Related Neurological Disorders: March 15-22, in Barcelona, Spain
KeyBanc’s Virtual Healthcare Conference: March 22-23
Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics, or ACMG: March 22-26, in Nashville, Tennessee
American Academy of Dermatology, or AAD, Annual Meeting: March 25-29, in Boston, Massachusetts

PDUFA Dates

Zogenix, Inc.’s (NASDAQ: …

Full story available on Benzinga.com